BDBM311633 Ex. Cpd. 85::US10807986, Example 85::US11046696, Compound 85

SMILES COCc1ccc(NC(=O)c2c(C#CCN3CCOCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1

InChI Key InChIKey=SFXVRNLGOSAWIV-UHFFFAOYSA-N

Data  9 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 311633   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311633(Ex. Cpd. 85 | US10807986, Example 85 | US11046696,...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311633(Ex. Cpd. 85 | US10807986, Example 85 | US11046696,...)
Affinity DataIC50: 0.700nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L) (i.e., RET with V804L mutation) kinase acti...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311633(Ex. Cpd. 85 | US10807986, Example 85 | US11046696,...)
Affinity DataIC50: 1.80nMAssay Description:RET (V804M) (i.e., RET with V804M mutation) kinase activity was measured using purified recombinant human RET (V804M) protein purchased from Eurofins...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311633(Ex. Cpd. 85 | US10807986, Example 85 | US11046696,...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311633(Ex. Cpd. 85 | US10807986, Example 85 | US11046696,...)
Affinity DataIC50: 0.700nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311633(Ex. Cpd. 85 | US10807986, Example 85 | US11046696,...)
Affinity DataIC50: 1.80nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET (V804L or V804M) (i.e., RET with V804L or V804M mut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/11/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311633(Ex. Cpd. 85 | US10807986, Example 85 | US11046696,...)
Affinity DataIC50: 0.200nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311633(Ex. Cpd. 85 | US10807986, Example 85 | US11046696,...)
Affinity DataIC50: 0.700nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Human)
Taiho Pharmaceutical

US Patent
LigandPNGBDBM311633(Ex. Cpd. 85 | US10807986, Example 85 | US11046696,...)
Affinity DataIC50: 1.80nMAssay Description:Regarding the conditions for measurement of in vitro inhibitory activity of compounds against RET kinase activity, the website of AnaSpec states that...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/27/2021
Entry Details
Go to US Patent